Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma

Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma

Immune checkpoint inhibitors (ICPi) targeting the PD-1/PD-L1 pathway have shown marked success in patients with advanced melanoma. However, 60–70% of patients fail to respond, warranting a therapeutic intervention that could increase response rates. We and others have shown that S-adenosylmethionine...

Full description

Bibliographic Details
Main Authors: Ali Mehdi, Mikhael Attias, Niaz Mahmood, Ani Arakelian, Catalin Mihalcioiu, Ciriaco A. Piccirillo, Moshe Szyf, Shafaat Ahmed Rabbani
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
DNA methylation
melanoma
S-adenosylmethionine
anti-PD-1
immunity
immune checkpoint inhibitors
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01361/full

Similar Items

Similar Items